To this end, we examined the selectivity of ganetespib-induced anti-proliferative effects in ErbB2+ cancer by overexpressing ErbB2 in two cancer cell lines that are typically ErbB2 deficient (MDA-MB-435 and MCF7) (Supplementary Fig. S1). This evidence concerns the gene ERBB2 and cancer.